For the quarter ending 2026-03-31, ANAB had $10,273K increase in cash & cash equivalents over the period. -$25,936K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -52,884 | 49,614 | 15,113 | -77,959 |
| Depreciation and amortization | 130 | 131 | 140 | 288 |
| Stock-based compensation | 14,218 | 8,506 | 9,157 | 18,409 |
| Non-cash interest expense | - | - | -22,515 | -37,667 |
| Accretion/amortization of investments, net | 8 | 340 | 1,130 | 3,264 |
| Amortization of right-of-use assets operating | 480 | 475 | 470 | 919 |
| Non-cash interest expense for sale of future royalties | 20,859 | 79,893 | - | - |
| Receivables from collaborative partners | -8,103 | -41,835 | 54,267 | -19,347 |
| Prepaid expenses and other assets | -1,501 | -971 | 303 | -944 |
| Accounts payable and other liabilities | -17,819 | -22,412 | -18,561 | -46,354 |
| Deferred income | 0 | - | - | - |
| Operating lease liabilities | -499 | -494 | -490 | -941 |
| Net cash used in operating activities | -25,919 | 97,997 | -27,356 | -50,944 |
| Purchase of investments | 0 | 0 | 19,656 | 176,755 |
| Sales and maturities of investments | 35,000 | 73,501 | 122,950 | 228,079 |
| Purchases of property and equipment | 17 | 1 | 12 | 74 |
| Net cash provided by investing activities | 34,983 | 73,500 | 103,282 | 51,250 |
| Payments for offering costs, net | - | 0 | 0 | - |
| Proceeds from public offerings, net of underwriters' fees | - | 0 | 0 | - |
| Payments for debt issuance costs | - | - | 0 | 0 |
| Proceeds from issuance of common stock | 14,021 | 12,212 | 336 | 1,713 |
| Repurchase and retirements of common stock | 0 | 3,384 | 9,720 | 55,522 |
| Proceeds from the sale of future royalties | - | 0 | 0 | 0 |
| Payment for net share settlement of equity awards | 0 | 0 | 0 | 1,451 |
| Payments for issuance costs related to the sale of future royalties | - | 0 | - | - |
| Principal repayment of liability for sale of future royalties | 12,812 | 51,962 | 1,007 | 23,828 |
| Net cash provided by (used in) financing activities | 1,209 | -43,134 | -10,391 | -79,088 |
| Net increase (decrease) in cash and cash equivalents | 10,273 | 128,363 | 65,535 | -78,782 |
| Cash and cash equivalents, beginning of period | 238,196 | 109,833 | 123,080 | - |
| Cash and cash equivalents, end of period | 248,469 | 238,196 | 109,833 | - |
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)